As previously reported, Canaccord initiated coverage of OrthoPediatrics (KIDS) with a Buy rating and $24 price target OrthoPediatrics has established a “strong position” in the pediatric orthopedic device market, says the analyst. The firm sees the company’s recent guidance update, in which it lowered guidance for 2025 and established 12%-plus as a baseline for annualized growth, as a de-risking event that leaves room for upside.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics initiated with a Buy at Canaccord
- OrthoPediatrics expands bracing portfolio with two new product launches
- OrthoPediatrics Corp’s Mixed Earnings Call Review
- OrthoPediatrics price target lowered to $26 from $42 at Needham
- OrthoPediatrics: Buy Rating Affirmed Amidst Growth Potential and Operational Efficiency